Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSG | P08311 | 1/20 | 0.49 |
| ▸ | CMA1 | P23946 | 1/20 | 0.49 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | TSHR | P16473 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.46 |
| ▸ | MEP1B | Q16820 | 1/20 | 0.45 |
| ▸ | AKR1C3 | P42330 | 4/20 | 0.44 |
| ▸ | HPGD | P15428 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2766417 | 0.85 | ALDH1A1 (0.52) | LMNAALDH1A1AKR1C3 | |
| SCHEMBL2768397 | 0.84 | CTSG (0.52) | CTSGCMA1SLC7A5MAPTTSHR | |
| SCHEMBL12440455 | 0.82 | ALDH1A1 (0.60) | MAPTTSHRLMNAALOX15MAPK1 | |
| SCHEMBL3249872 | 0.82 | CTSG (0.53) | CTSGCMA1SLC7A5MAPTTSHR | |
| SCHEMBL392888 | 0.81 | ALDH1A1 (0.45) | LMNAALDH1A1AKR1C3CYP3A4ROCK1 | |
| SCHEMBL13181463 | 0.80 | ALDH1A1 (0.55) | ALDH1A1SMN1; SMN2CYP19A1 | |
| SCHEMBL12750998 | 0.79 | CTSG (0.51) | CTSGCMA1SLC7A5MAPTTSHR | |
| SCHEMBL12400239 | 0.78 | SLC7A5 (0.68) | CTSGCMA1SLC7A5MAPTTSHR | |
| SCHEMBL4615715 | 0.77 | HTR6 (0.53) | LMNAALDH1A1SMN1; SMN2CYP19A1 | |
| SCHEMBL18151609 | 0.76 | TSHR (0.47) | CTSGCMA1TSHRLMNAMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1751133-B1 | COMPOSITIONS USEFUL AS INHIBITORS OF ROCK AND OTHER PROTEIN KINASES | VERTEX PHARMA (US) | 2010-04-14 | — | — | EP | disclosed |
| US-7531556-B2 | Compositions useful as inhibitors of rock and other protein kinases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2009-05-12 | — | — | US | disclosed |
| US-7514448-B2 | Azaindoles useful as inhibitors of rock and other protein kinases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2009-04-07 | — | — | US | disclosed |
| US-7514448-B2 | Azaindoles useful as inhibitors of rock and other protein kinases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2009-04-07 | — | — | US | disclosed |
| US-7514448-B2 | Azaindoles useful as inhibitors of rock and other protein kinases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2009-04-07 | — | — | US | disclosed |
| CN-101014597-A | Azaindoles useful as inhibitors of rock and other protein kinases | VERTEX PHARMA (US) | 2007-08-08 | — | — | CN | disclosed |
| EP-1756108-A2 | AZAINDOLES USEFUL AS INHIBITORS OF ROCK AND OTHER PROTEIN KINASES | Vertex Pharmaceuticals Incorporated (US) | 2007-02-28 | — | — | EP | disclosed |
| EP-1751133-A2 | COMPOSITIONS USEFUL AS INHIBITORS OF ROCK AND OTHER PROTEIN KINASES | Vertex Pharmaceuticals Incorporated (US) | 2007-02-14 | — | — | EP | disclosed |
| US-20060019956-A1 | Compositions useful as inhibitors of rock and other protein kinases | VERTEX PHARMACEUTICALS INCORPORATED | 2006-01-26 | — | — | US | disclosed |
| US-20060003968-A1 | Azaindoles useful as inhibitors of rock and other protein kinases | VERTEX PHARMACEUTICALS INCORPORATED | 2006-01-05 | — | — | US | disclosed |
| WO-2005105780-A2 | COMPOSITIONS USEFUL AS INHIBITORS OF ROCK AND OTHER PROTEIN KINASES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2005-11-10 | — | — | WO | disclosed |
| WO-2005103050-A2 | AZAINDOLES USEFUL AS INHIBITORS OF ROCK AND OTHER PROTEIN KINASES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2005-11-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060003968-A1 | Azaindoles useful as inhibitors of rock and other protein kinases | ROCK2, ROCK1, TNK2 | CTSG 3186/4885CMA1 1388/4885SLC7A5 4028/4885 |
| US-20060019956-A1 | Compositions useful as inhibitors of rock and other protein kinases | ROCK1, ROCK2, PRKCH | CTSG 1694/4885CMA1 1109/4885SLC7A5 4471/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.